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Abstract
Human papillomaviruses (HPV) are naked particles composed of 72 subunits, each formed
by 2 structural proteins designated L1 and L2 (L = late). HPV does not grow outside of
squamous epithelium cells, in which it infects the suprabasal prickle cell layer. The viral
double-stranded DNA (vDNA) has about 8 kilobase pairs (kbp) and also encodes several
non-structural polypeptides, designated E1–E7 (E = early). At least 3 early oncoproteins
(E5, E6, and E7) induce host cell proliferation, driving them into permanent division.
During long-term latency, the circularized HPV DNA may get integrated into the host
cell DNA molecule. The circular HPV DNA is then interrupted, usually within the E2
open reading frame (ORF), which then cannot exert its regulatory (feedback) effect on the
early gene expression. The increased expression of E6/E7 proteins seriously affects the
regulation of host cell division mainly via dysregulation of the functions of p53 and Rp
proteins. HPV infects the female genital tract representing the main cause of cervical
dysplasia and subsequent squamous cell carcinoma (SCa). The HPV isolates exist mainly
in the form of amplified DNAs; based on the similarity and/or variations (dissimilarity)
of their L1 capsid polypeptide sequence, 96 human genotypes were included into five
genera of the Papillomaviridae family. The clinically most important genotypes that cause
lesions at mucosal membranes and/or on the skin, belong mainly to the Alphapapillo‐
mavirus genus. The genotypes, associated with severe dysplastic changes and/or cervical
cancer, were designated as high risk (HR-HPV). The prevalence of the integrated HPV
DNA sequence over the episomal molecules appears in a proportion smears-graded LSIL
(low-grade squamous intraepithelial lesion). Later on, carrier cells revealing the integrated
HPV genome expression the oncoproteins (E6/E7) clearly prevail especially in HSIL (high-
grade squamous intraepithelial lesion) smears and in the cervical cancer itself. What is
crucial for the modern diagnostic of cervical dysplasia, is the p16/INK4A (inhibitor kinase)
polypeptide, which itself represents a form of cell defense against the viral oncogenic
proteins. The p16 antigen shows a continuous parabasal staining in the CIN I lesion. If
dysplastic cells occupy at least one half (or two thirds) of squamous epithelium, the
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designation CIN II/HSIL is correct, and at the stage of CIN III/HSIL, dysplastic cells replace
the entire squamous epithelium. Another frequently used immunohistochemical marker
of intraepithelial cervical dysplasia so far is the Ki-67 antigen, which occurs in the nuclei
of proliferating and/or repeatedly dividing (immortalized) cells. Women revealing p16-
positive ASCUS (atypical smear cells of unknown significance) as well as those showing
LSIL (low-grade cytological changes) should be examined for the presence of the HPV
DNA. The detection of HPV DNA alone, that is, in the absence of cytological screening,
has a relatively lower prediction value, though the HR HPV positive DNA test in the
absence of morphological alterations may in part predict the possible progression into
malignancy. Nevertheless, only the combined cytological as well as molecular follow-
up (cervical smear examined for cytology as well as for HPV DNA) is regarded for the
most reliable diagnostic approach.
Keywords: Human papillomavirus, Cervical intraepithelial neoplasia (CIN), Cervical
dysplasia, Squamous cell carcinoma, p16/INK4A Polypeptide, Ki-67 polypeptide, Lab‐
oratory diagnostic, PA smears, Squamous intraepithelial lesion (SIL), Liquid-based cy‐
tology (lbc), Cervical biopsy, Histology, HPV DNA testing
1. Introduction
Virus infection had been for a long time anticipated in the pathogenesis of cervical cancer. The
suspected role of herpes simplex virus 2 (HSV 2) early protein as suggested by Aurelian et al.
[1] was not confirmed, since several carefully designed prospective and/or serological studies
following the significance of elevated anti-HSV 2 antibody levels did not confirm any associa‐
tion. Although certain isolated DNA fragments coming from the HSV genome may transform
the tissue culture cells of rodent origin, their relevance in the induction of human cervical
carcinoma has not met any further approval [2, 3]. Contemporarily, the human papillomavi‐
rus (HPV) has been accepted to represent the most probable infectious agent in respect of cervical
cancer [4]. During the last decades, a great bulk of convincing data has accumulated in favor of
the latter assumption, which has become widely accepted. Thus, based on substantial clinical
and biological evidence, strong relationship exists between HPV infection and the develop‐
ment of cervical cancer. Nevertheless, in line with a few but independent observations, a
hypothesis has repeatedly emerged saying that HSV 2 co-infection might represent an acceler‐
ating cofactor for cervical carcinoma formation [5]. Novel reports from Brazil and/or some other
comparative studies on the given issue, which had been performed simultaneously among
Indonesian and Swedish population, confirmed the possible role of HSV 2 in the former but not
the in the latter geographical area [6].
Our paper reconciles the role of latent HPV infection (mainly based on the detection of
corresponding DNA sequences and/or their fragments) in the stratified squamous epithelium
cells of oral, vaginal, and/or anal mucosa (especially at their transition sites to cylindrical
epithelium, such as uterine cervix) and/or in the keratinized squamous skin epithelium cells.
Regarding to the role of the HPV genome in the pathogenesis of cervical cancer, we shall point
at the importance of a complex diagnostic approach overcoming the possible barriers between
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scientific disciplines such as virology, pathology, and molecular biology on one hand and
explain the need of the rapid application of novel achievements in diagnostic pathology,
biochemistry, cytology as well as in the clinical practice. Despite of the difficulties of any
interdisciplinary approach, the introduction of molecular virology (such the HPV DNA test)
and immunohistochemical procedures (p16 and Ki-67 antigen detection) into diagnostic
pathology and/or cytology when done in close cooperation with gynecologists has led to a
dramatic decrease of the frequency of cervical cancer in several European countries, Slovakia
not excluding. Reporting the frequency of positive cervical smears was registered in the terms
of the conventional Papanicolaou (PA) test, which is still most suitable for large-scale screen‐
ing. Table 1 summarizes six annual reports of one of several Alpha medical Company Ltd
Diagnostic Centres, which were destined for domestic insurance companies. The categories of
classification of cervical dysplasia in given statistics do not correspond to the Bethesda
classification system [7, 8]. According to the latter, atypical squamous cells of unknown
significance (ASCUS) should be distinguished from non-neoplastic reactive changes of cervical
squamous epithelium cells using the criteria summarized in Table 2. The squamous intraepi‐
thelial lesion (SIL) can be recognized by the presence of dysplastic cells, which show either
mild (low grade) or more severe (high grade) alterations (Table 3). The original cytological
nomenclature used to describe the appearance of cells in conventional PA smears before the
introduction of Bethesda classification system has been repeatedly compared by several
authors [9, 10] with the recently adopted definitions. Based on these data, we proved the
individual categories of the so-called MKCH classification system (Slovak abbreviation for the
expression International Classification of Diseases). To achieve an upmost precise interpreta‐
tion, we used terms essentially resembling to the CIN (cervical intraepithelial lesion) classifi‐
cation, namely a similar three-degree scale (I—low, II—medium, and III—high). Evaluating
in detail each protocol from the archives of the Pathology Diagnostic Centre of Alpha medical
Company in Martin coming from a single-year period, that is, the year 2015 (compare Table
4), we found that the medium-grade cervical dysplasia category from the MKCH statistics in
fact encompassed as many as 64% of smears-graded LSIL, while the proportion smears scored
HSIL in the same category was approximately 6%. Noteworthy, another 6% fall into the group
of patients with negative smears and the rest protocols revealed the diagnosis of ASCUS and/
or ASC-H (in 24%). It should be mentioned that out of 516 samples of the given MKCH
category, 110 had been repeatedly tested patients (these women were re-examined within 4–
6 months intervals, i.e., at least twice during the same year). Thus, the MKCH category
“medium-grade cervical dysplasia” consisted of 516 smears coming from 457 women. In the
group of repeatedly examined patients, 10% underwent spontaneous healing during the
relatively short 1-year follow-up period (data not shown). The repeatedly negative smears
came mainly from patients, which were at first examination scored ASCUS. Unfortunately,
their HPV DNA status is not always determined, even though in this group (“medium-grade
cervical dysplasia”) during the year 2015, altogether 162 of smears were tested HPV DNA,
from which 74 were positive (a proportion of 39.5%), while 13 were HPV type 16 positive and
6 were HPV type 18 positive. While only 32% of screened patients were examined by cytology
as well as for HPV, many HPV tests were made in the absence of cytology and/or vice versa
(compare paragraphs 4 and 5, see also Table 12).
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Diagnosis Patient number Per cent  Modified4
Positive Total examined
Low-grade cervical
dysplasia*,1
3070** 206,317 1.5% 3943 (1.9%)
Medium-grade cervical dysplasia2 1456 0.7% Cancelled
High-grade cervical dysplasia3 263 0.13% 466 (0.23%)
ASCUS (includes also ASC-H, from
low and medium dysplasias)1,2
230 (0.13%)
Carcinoma in situ 36 0.02% No change
Cervical (spinocellular)
carcinoma
16*** 0.007% No change
1Corresponds to LSIL (88%) and/or ASCUS (12%).2Corresponds to LSIL (60%), ASC-H/ASCUS (18%) and/or to HSIL
(10%).3Corresponds to HSIL.4Modified according to above mentioned1,2,3, remarks (see text for details).*Designation of
given statistical categories according to author´s translation (from Slovak).**Positive smears after excluding the
negative ones or those referred to as reactive changes.***Including 5 cases showing invasive growth into distant into
(surrounding) tissues.#From report of Pathology Diagnostic Centre, Alpha medical Company Ltd, Martin (Slovakia)
for domestic authorities (with permission).
Table 1. Frequency of cervical dysplasia and/or cervical cancer by screening of cytological smears from 1 January 2010
to 31 December 2015#.
Atypical cells of unknown significance (ASCUS) Reactive changes due to inflammation
Size of nuclei increased significantly (three times) Slightly enlarged nuclei (up most two times)
Cells revealing doubled nuclei may be present
Moderately dense chromatin staining Slight hyperchromatic staining only
The fine granular chromatin is dispersed throughout nucleus
Nuclei may be slightly elliptic, but regularly are nearly round shaped
The nuclear/cytoplasm ratio (N/C) in moderately increased
Atrophic or shrink nuclei
The cytoplasm may be vacuolated
Polymorphonuclear leukocytes are present
Bacteria may be present
Koilocytes (proving HPV) can be recognized
Hyperchomatosis, dense chromatin granules.
The nuclear membrane has irregular appearance
A faint perinuclear ring may be visible
* Based on the data from corresponding manuals [11, 12].
Table 2. Definition of ASCUS versus reactive changes in cervical smears*.
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LSIL HSIL
Nuclei relatively enlarged (over three times) Nuclei increased in size, shrink cytoplasm
Dysplastic cells frequent, smaller in size
The small dysplastic squamous cells form larger aggregates
The N/C ratio increased not only due to larger nuclei but also by loss of cytoplasm
The size of nuclei varies, multiple nuclei* (larger polykaryocytes)**
Evident hyperchromatosis, dark nuclei
Chromatin shows irregular distribution
Relatively fine nuclear granules Coarse grainy chromatin
Occasionally irregular nuclear membrane Undulate nuclear membrane
Nucleoli may be visible Nucleoli are not seen
The cytoplasm may show keratin granules
* Based on data from corresponding manuals [11, 12].
Table 3. Definition of low-grade versus high-grade squamous intraepitelial lesion (SIL)*.
Diagnosis Patient number Per cent
Positive Total examined
Low-grade squamous
intraepithelial lesion*
1324 37,414 3.54%
High-grade squamous
intraepithelial lesion**
151 0.4%
Atypical cells of
unknown significance***
231 0.621%
Carcinoma in situ 3 0.04%
Cervical carcinoma (SCa)1 2 0.005%
* LSIL ** HSIL *** ASCUS.
1 Squamous cell carcinomas.
Table 4. The frequency of cervical dysplasia and/or cervical cancer by screening of cytological smears from 1 January
2015 to 31 December 2015.
Alternatively, we analyzed a proportion of still available original protocols from a limited
number of women (300 at random chosen patients were re-evaluated out of 1425, i.e., 20.6%),
in order to assess the estimate number of LSIL and HSIL cases in result of cancelling the
undesired category of “medium-grade dysplasia”. Despite of some doubts concerning the
precision of such calculations, we could demonstrate the decreased incidence as well as a
significantly lower morbidity for cervical carcinoma within the last 6-years period. Regarding
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to the frequency of 7.5 positive smears out of 100,000 samples enrolled, and comparing this
number with the overall morbidity rate of 15.4/100,000 as reported for Slovakia in 1999 [13],
the estimated decrease of cervical carcinoma cases should be much higher than 50%. Namely,
the former number reflects the relative proportion of positive samples out of the total enrolled,
while the latter represents the frequency of disease in whole women population (either in the
fertile and/or post-fertile age). The estimated proportion of women examined in comparison
with the total woman population in given age might range from 10 to 20%. Even if this
proportion of followed may not be correct, the decreased morbidity for cervical cancer in
Slovakia during the last decade might be at least tenfold. Furthermore, Table 1 also shows that
at least 6% (by minimal rate 263/3070) but not more than 12% (by maximal rate 466/3943) of
smears which had been scored LSIL progressed into the stage of HSIL. For the above-men‐
tioned minimal rate, the intermediate MKCH category was not taken into account; for the
maximum rate, it has been split (modified) into corresponding Bethesda categories as ex‐
plained above. Thus, regardless to any imperfections of both calculations, which may arise
from comparison of the Tables 1 and 4, our data point at an increased incidence of newly
emerging LSIL cases. Namely, the average positive rate among the smears, which was in the
range of 1.5–1.9% during the last 6-years period, has reached 3.5% in the year 2015 (an increase
of 180%). As already suggested in our previous paper [14], and confirmed by others, the
probability of transition from LSIL and/or ASC-H cases into HSIL strongly depends on the
presence of HPV as detected by one of the available HPV DNA tests [15, 16]. The great majority
of the ASCUS cases and up to 85% of LSIL cases (especially in the absence of HPV DNA) might
undergo spontaneous healing as shown in next paragraph.
2. The role of human papillomavirus (HPV) in the pathogenesis of cervical
dysplasia and cancer
The first mammalian papillomavirus (PV) was described by Shope and Hurst [17], who
characterized the transmissible nature of cutaneous papillomas arising in wild cottontail
rabbits. The narrow host range of PVs in culture to sites with stratified squamous epithelia
that is either cornified (skin) or non-cornified (mucosa) was overcome by introducing molec‐
ular technics such as the DNA extraction, the polymerase chain reaction (PCR), and vDNA
sequencing allowing to identify the genes of the PV DNA regarding to the function of
corresponding proteins. The papillomaviruses (PVs) comprise a group of non-enveloped
epitheliotropic DNA viruses that predominantly induce benign lesions of the skin (warts) and
mucous membranes (condylomas). Some PVs have also been implicated in the development
of epithelial malignancies, especially in the cancer of uterine cervix, certain tumors of urogen‐
ital tract, and upper airway cancers [18]. Due to given relationships, an increasing amount of
information has accumulated from sequencing results of various PV DNAs. Later on, the PVs
were classified according to the host species they infect, so that the PVs of human origin were
designated as human PVs (HPV). Officially recognized by the International Committee on the
Taxonomy of Viruses (ICTV), the former Papovaviridae family now falls into two separate
families, Papillomaviridae and Polyomaviridae [19]. The reason being the missing helicase motif
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in the HPV E1 protein, a domain stretching longer than about 230 amino acids (aa) within the
analogous non-structural HPV polypeptide, which otherwise has some similarity with the
SV40 T-antigen, the parvovirus NS1 protein, and with a planarian virus-like element [20].
Among the most extensively studied HPV genomes, nearly 100 genotypes were described
based on the at least 90% nucleotide homology of sequence encoding one of 2 structural capsid
proteins (the L1 protein sequence). The L1 ORF is the most conserved gene within the genome
and has therefore been used for the identification and classification of new HPV types
corresponding to later characterized species is shown in Table 5. It should be mentioned that
sorting into species and genus has some theoretical and/or scientific importance, but for
practical reasons, the old genotype classification is still in use (Table 6). A new HPV isolate is
recognized as such, if its complete genome has been cloned and sequenced to determine in
which extent the L1 ORF differs from the closest known HPV genotype. If a more than 10% bp
difference can be found that is a distinct genotype. Differences between 2 and 10% homology
define a subtype and <2% difference reveals a variant. The closely related HPV types HPV-2
and 27, HPV-6 and 11, and HPV-16 and 31, which cause common warts, genital warts, and
cervical cancer, respectively, are excellent examples of numerous consistencies between
phylogeny and pathology. Furthermore, the HPV genotypes could have been distinguished
as high risk (HR) and low risk (LR) according to their ability to transform cells, due to their
relationship to cervical dysplasia and/or cancer, and according to their frequency. The
squamous carcinoma (SCa) cells and/or the cells in epidermodysplasia veruciformis (EV) harbor
multiple genome copies of specific HPV types, especially HPV5 and HPV8, but also of HPV14,
HPV20, and a few others [21–23]. Their transcripts have been described in several the so-called
EV-associated SCa cells [24]. In 2009, HPV5 and HPV8 were classified by IARC as “possibly
carcinogenic” in EV patients [25].
Genus Properties  Species  Genotype(s) Clinical significance
Alphapapillomavirus Mainly 1 HPV32, HPV42 Benign lesions, oral or genital mucosa, LR
mucosa but 2 HPV3, HPV10 genotypes, benign cutaneous or mucosal
also skin HPV28, HPV29 lesions,
lesions; HPV78, HPV94
conserved E5 3 HPV61, HPV72, LR genotypes, mucosal lesions
ORF within HPV81, HPV83,
the ERL* ; HPV84
HR genotypes 4 HPV2, HPV27, Skin warts (common), frequently benign,
immortalize HPV57 LR genotypes,
keratinocytes, 5 HPV26, HPV51, HR genotype, mucosa lesions
HPV69, HPV82
6 HPV30, HPV53, HR genotypes, mucosa lesions,
HPV56, HPV66 some are LR genotypes
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Genus Properties  Species  Genotype(s) Clinical significance
7 HPV18, HPV39, HR genotypes, mucosal lesions
E5 ORF is HPV45, HPV59,
different HPV68, HPV70,
8 HPV7, HPV40, LR genotypes, butcher warts, skin and
HPV43 mucosa
9 HPV16, HPV31, HR genotypes, mucosal lesions
HPV33, HPV35,
HPV52, HPV58,
HPV67
10 HPV6, HPV11, LR genotypes, rarely verrucous carcinoma
HPV13, HPV44,
HPV73, HPV74 HR genotypes, mucosal (cervical) lesions
11 HPV34, HPV73 (dysplasia and carcinoma)
13 HPV54 LR genotype, mucosal lesions
15 HPV71 LR genotype, mucosal lesions
Betapapillomavirus Latent 1 HPV5, HPV8, Mainly benign cutaneous lesions
infection HPV12, HPV14
possible in HPV19, HPV20
general HPV21, HPV25
population HPV36, HPV 47,
HPV93,
2 HPV9, HPV15, Commonly associated with EV,
HPV17, HPV22, mucosal lesions and detection of vDNA in
HPV23,HPV37, immunosuppression,
HPV38,HPV80 most frequently LR genotypes
3 HPV 49, HPV75, LR genotypes, benign cutaneous
HPV76
4 Candidate types 60 Pre-malignant cutaneous
5 and 88 Pre-malignant cutaneous
Gammapapillomavirus 1 HPV4, HPV65 Cutaneous lesions, intracytoplasmic
HPV95 homogenous inclusion bodies
2 HPV48 Cutaneous lesions
3 HPV50 Cutaneous lesions
4 HPV60 Cutaneous lesions
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Genus Properties  Species  Genotype(s) Clinical significance
5 HPV88 Cutaneous lesions
Nu-papillomavirus Several not 1 HPV41 Bening as well as malignant cutaneous
assigned
ORFs,
Mu-papillomavirus Human PV, 1 HPV1 Heterogenous cytoplasmic inclusions,
inclusion 2 HPV63 filamentary cytoplasmic inclusions,
bodies LCR/URR has 982 bp
specific
1 According to deVilliers et al. [30]; 2 epidermodysplasia verruciformis. * ERL = the DNA segment between E and L
ORFs.
Table 5. Classification of papillomaviruses and the list of their important genotypes.
Disease Frequent association Rare association
Skin infection
Deep plantar warts 1, 2 4, 63
Common warts 2, 1 4, 26, 27, 29, 41, 57, 65, and 77
Butcher’s warts 7, 2 1, 3, 4, 10, and 28
Epidermodysplasia
verruciformis (ER)*
Skin carcinoma
associated with ER
2, 3, 5, 8, 9, 10, 12, 14, 15, and
17
5 and 8
19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, and 70
Anogenital
infection
Condyloma
acuminatum
6, 11 30, 42, 43, 44, 45, 51, 54, 55, 70
Intraepitelal dysplasia
(CIN I a CIN II/III)
6**, 11**, 16, 18 (16, 18, 74, 86) 6, 11, 26, 31, 33, 35, 39, 42, 43, 44, 45,
51, 52, 53, 56, 58, 66, 73, and 82
Carcinoma in situ; and invasive
carcinoma
16, 18, 31, 45 33, 35, 39, 51, 52, 56, 58, 59, 66, 67, 68, 73, and 82
Recurrent laryngeal papilloma 6, 11
Conjuctival papilloma 6, 11, and 16
* Congenital skin lesion with high sensitivity to HPV infection.
** Mainly in CIN I/LSIL, CIN II and/or non-invasive forms CINIII/HSIL and/or CIN III+/HSIL.
# According to Bonnez [31].
Table 6. Clinical relevance of high-risk (in bold) and low-risk HPV genotypes according to their frequency.
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The HPV virions are small non-enveloped capsids 55 nm in size and of icosaedral symmetry.
They are composed of 72 subunits formed by 2 structural proteins (L1 and L2, L = late), which
are synthesized at the late intervals of productive replication cycle. The viral double-stranded
DNA (vDNA) has about 8 kilobase pairs (kbp); it encodes 7 or 8 non-structural polypeptides,
designated E1–E8 (E = early). The transcription of viral mRNA is directed clockwise under the
control of two promoters, namely the early promoter (P97) and the late promoter (P670) sequence.
In between the initiation codon for the transcription of E1 polypeptide ORF (open reading
frame) and the stop codon for the L2 capsid protein ORF, an approximately 1.1 kbp long control
repeat (LCR) is situated that contains the origin of vDNA replication as well as several binding
sites for the binding of viral E2 and/or E1 regulatory proteins (Table 7). In addition to the
motifs for down-regulation of the productive replication cycle (on the basis of a feedback
mechanism), the LCR (also referred to as the URR, upstream regulatory region) contains
enhancer sites for attachment of cellular transcription cofactors promoting the binding of
cellular RNA polymerase to accomplish viral mRNA synthesis.
Protein MW Properties  and function
E1 68–76
kDa 
Binds to the regulatory long control repeat (LCR/URR) upstream from the E6/E7 ORF promoters.
Forms a heterodimer with E2, associates with H1 histones and with cyclins, especially with cyclin E.
E2 40–58
kDa 
Activates viral mRNA transcription, binds to the LCR/URR sequence, associates with the E1 protein;
acts as cofactor of vDNA replication; operates at distribution of newly copied vDNA molecules during
cell division (also in latency). Suppresses the expression of E6/E7 proteins and interacts with the L2
capsid polypeptide (especially at productive virus replication). Induces apoptosis.
E3 10–17
kDa 
Function unknown.
E4 Associates with the L1 capsid polypeptide and facilitates virion formation (during productive
replication); co-localizes with cytokeratins being produced in the medium and upper spinous layers.
1 Long control repeat/upstream regulatory region.
Table 7. Basic functions of HPV-coded early (non-structural) polypeptides involved in the replication and latency.
Protein Molecular
weight
Properties and function 
E5 10 kDa Increases and prolongs the activities of receptors interacting with external growth factors such
as EGF and/or PDGF2 by binding to their cytoplasmic domain. Inhibits the acidification of
endosomes, binds to ATPase within the membranes of vacuoles and increases the stability of
the engulfed EGF/EGFR complexes. Activates cellular transcription factors such as AP1* and
signal transmission mediating proteins such as c-Jun** and/or c-Fos.
E6 16–18
kDa
Binds to the pivotal cell division regulator p53 (cellular anti-onc protein), enhances its
degradation by ubiqitination (most efficiently acting are the E2 from HPV16 and/or HPV18
genotypes).
E7 10–14
kDa
Binds to the retinoblastoma (Rb) protein (its p107 and p130 forms) , which regulate cellular
DNA transcription via binding or release of the transcription initiation factor E2F (in response
to phosphorylation of the Rb associated cdk complex). Activates mainly cyclins A and E,
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Protein Molecular
weight
Properties and function 
especially influencing the translocation into nucleus of the transcription cofactor AP1.
Activates the histone deacetylase (HDAC) acting at the level of the so-called epigenetic
regulation of transcription by removing its blockade.
1 Epidermal growth factor 2 Platelet-derived growth factor, * Activator protein 1, * Cellular ju-na-na *** Cyclin-
dependent kinas.
Table 8. Basic functions of the HPV-coded early (non-structural) oncoproteins.
The E2 polypeptide was initially described as a transcriptional activator [26] capable to initiate
viral transcription through the E2 recognition elements located within early promoter (for
HPV16, it is the above mentioned P97, while alternatively, for HPV18, it is the P105). As described
below in more detail, tumorigenesis is mediated by an integrated HPV DNA fragment,
encompassing the E6 and E7 genes exerting transformation activity (Table 8). During pro‐
ductive (vegetative) virus replication in human squamous epithelial cells, the essential
activities displayed either by the HPV type 16 P97 or by the HPV type 18 P105 promoters can be
repressed by the full-length E2 polypeptide, which binds to one of the four E2 binding sites
upstream of either P97 or P105 [27]. The E2 protein also facilitates long-term persistence of HPV
genome in host cells by episomal maintenance providing a mechanism ensuring the distribu‐
tion of viral genome within the dividing epithelium and its segregation into daughter cells [28,
29]. This can be achieved due to the association of E2 with the mitotic spindles, when it interacts
with condensed mitotic chromatin and thereby ensures that the viral genome (which dupli‐
cates within the dividing host cell during cellular DNA synthesis) gets attached to nuclear
envelope at anaphase and reforms during telophase. The duplication of viral genome during
mitosis is accomplished by means of the cellular DNA polymerase, which becomes modified
by another early HPV-coded protein, the El polypeptide. The E1 is required for both the
initiation and elongation of viral DNA synthesis being accomplished by the cellular DNA
polymerase complex by means of its ATPase and DNA helicase activities. The E2 can complex
with E1 to strengthen its affinity for binding to the origin of vDNA replication. The papillo‐
mavirus E2 protein has several well-characterized regulatory functions affecting viral tran‐
scription, viral DNA replication as well as long-term plasmid maintenance. In contrast to the
duplication of HPV DNA, which is the main strategy to ensure long-term persistence of viral
genome, in the course of acute virus replications, the necessary point is to generate many
genome copies which will be packaged into virions. Why that process occurs only in the
terminally differentiated cells of the upper squamous epithelium layer and in the benign
vegetative vDNA replication, is not known. The switch in question may involve the presence
or absence of cellular cofactors expressed in the differentiating keratinocytes, i.e. only within
the cytokeratin forming upper squamous epithelium layer. As described later, these cells, if
previously proliferating papilloma cells. The mechanisms regulating the switch from plasmid
maintenance to vDNA replication not known. This switch may envolve the presence or absence
of cellular cofactors expressed in the differentiating keratinocytes, thus is occurs only within
the cytokeratin forming upper squamous epithelium layer. As described later, these cells, if
previously infected within the lower squamous epithelium layer, then show typical morphol‐
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ogy, the so-called koilocytes. Clearly, the relatively increased levels of HPV proteins such as
E1 or E2 (or their modifications) may change the appearance of terminally differentiating
keratinocytes. One might anticipate that the vegetative DNA replication occurs bi-direction‐
ally, through a theta structure intermediate or by a rolling circle mode, which is the principle
of vDNA replication in general. Finally, the virion assembly must take place in the nuclei of
terminally differentiated keratinocytes, which also contributes to koilocyte formation. The
nascent capsids might randomly attach to the HPV DNA, and are further stabilized by the
formation of disulfide bonds between conserved cysteines on adjacent L1 monomers acquiring
resistance to proteolytic digestion. Taken together, as result of productive replication, the
virions form large aggregates within the nuclei of infected keratin forming upper squamous
epithelium cells, which then regularly show koilocytosis [32], but rarely reveal cytoplasmic
inclusion bodies (see Table 5 for details).
The newly produced HPV virions do not appear outside of squamous epithelium cells, and its
productive replication is closely bound to the suprabasal, mainly medium and upper slayer
of dividing keratinocytes. At infection, the HPV virions preferentially bind to heparan sulfate
proteoglycans (HSPGs) on the basement membrane or to the basal stem cells, which may be
exposed to environmental influence at sites of epithelial trauma or permeabilization. The
differentiating squamous epithelium cells cannot become infected. To achieve selective
infection of basal differentiating squamous epithelium cells, the initiation of infection prefer‐
entially requires attachment to the basal stem cells layered at the basal membrane of stratified
squamous epithelium [33–35]. The basement membrane-bound virion undergoes a conforma‐
tional change of its L2 capsid protein that exposes a highly conserved N-terminal peptide motif
to cleavage by furin or the closely related pro-protein convertase [36]. There is a remarkably
long delay of 1–3 days between the capsid cell surface binding and its penetration resulting in
the onset of viral genome transcription. Itself the internalization of capsids as starts from the
attachment to cell surface until the uncoating process begins lasts at least 2–4 h and is very
asynchronous. The endocytosis as well as the consequent transmembrane trafficking of HPV
capsids is not fully understood. Penetration of engulfed capsids may be initiated either from
the acidified late endosomes, in which the L2 conformation change takes place, or by clathrin-
dependent uptake [37]. The penetrated virions are transported from the internal membrane
surface by involutions called vilopodia, namely from their leading edge to the central cell body
via actin-directed retrograde flow [38]. Classical observations testify that there is extremely
difficult to isolate and propagate any HPV types in conventional human cell cultures [39].
During the last decade, several details of HPV induced continuous host cell proliferation have
been elucidated. It became clear that three non-structural HPV-coded oncoproteins, namely
E5, E6, and E7 (Table 8) are involved in host cell immortalization, which later on, under the
conditions of continuous host cell division results in malignant transformation. It should be
mentioned that the transformation as such is a multistep process, launched by the virus-coded
oncoproteins as suggested the “hit and run” hypothesis. The E5 protein enhances the sensi‐
tivity of HPV carrier cells to external proliferative stimuli, such as the epidermal growth factor
[40]. It also binds to the growth factor receptors, for example, to the platelet growth factor
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receptor (PDGFR), and activates the signal transmission in a ligand-independent manner [41,
42].
Because the integrated vDNA regularly encompasses just the ORFs of E6 and E7 oncoproteins
along with the closely positioned LCR sequence, a continuing and increased expression of E6/
E7 proteins occurs which seriously affects the regulation of host cell division in direction of its
down-regulation [43, 44]. The E6 polypeptide binds the pivotal cell division inhibiting p53
protein [45], while E7 polypeptide binds the retinoblastoma (Rb) protein and the cyclin
inhibitory proteins p27 and p21 [46]. The HPV-coded oncoproteins E6/E7, when expressed in
significant amounts, continuously drive the host cell from the phase G1 to phase S (synthesis),
in which the replication of cell DNA proceeds in an unlimited manner. Noteworthy that
immortalization and the process of cancerogenesis are not the same, since the latter is much
more complex being related to several chromosomal alterations and to increased number of
c-myc gene copies (probably arisen due to repeated host cell DNA sequence transpositions), a
finding even proportional to the grade of HPV driven dysplasia [47]. In low-grade dysplasias
(such as CIN I/LSIL), only a restricted number of the HPV oncogenes is expressed.
Nevertheless, E6 and E7, which have several other activities (Table 8), appear to be the main
drivers for the progression to high-grade dysplasia and later on to cancer, by orchestrating a
series of pathogenic changes. Both are transcribed from the same major early promoters located
within the LCR region of their genome. As a rule, the expression of the episomal (not yet
integrated) HPV genome is restricted to E6 and E7 polypeptides, which are present in the
parabasal, lower layer of squamous epithelium. Here, the viral genome undergoes a regulated
duplication along with the host cell proliferation, which is under physiological conditions
regulated by corresponding stimuli. The E6 protein is expressed at substantially lower levels
than E7, and in early LSIL lesions, since the level of E7 may be more limited than that of E6.
Noteworthy, both genes are expressed from a single promoter (latency associated and different
from the above-mentioned vegetative ones); their transcripts are alternatively spliced by a
post-translation mechanism determining as well as regulating their relative level within the
carrier host cell. Integration of the HPV DNA fragment into cellular DNA via non-homologous
recombination represents a key change towards immortalization that appears to stabilize the
high expression of E6/E7, which, in turn, becomes frequently associated with more severe
lesions. Integration may still not occur in great majority of CIN I/LSIL lesions, but is present
by an increased rate in HSIL/CIN II and/or CIN III lesions, and is the most frequent in pre-
invasive cancer (Ca in situ). As a rule, whoever, the integrated E6/E7 ORF containing the HPV
DNA fragment is at high probability found in the CIN III lesions. The frequency of viral DNA
integration may vary with the HPV genotype, being more frequent for the high-risk (HR)
genotypes such as HPV18 and/or HPV16.
The integration of vDNA and/or its fragment occurs due to interruption of its sequence, which
can appear at many sites throughout the genome, but is found preferentially at fragile genomic
sites, which undergo nicking and cutting in association recombination and/or translocation
events of the host cell genome. In certain cases, practically the rest of whole genome may be
deleted, so that only the E6 and E7 ORFs remain intact and ready for the transcription along
with the nearby located LCR sequence, containing the crucial promoter and enhancer signals
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lying upstream of the integration site [48]. In a given in vitro immobilized keratinocyte culture,
the integration process usually involves only one locus or a few loci. The E6/E7 ORF tran‐
scription slowly increases due the loss of the feedback block provided by the viral E1 and E2
proteins, which ORFs had been either deleted or at least disrupted. This situation permits the
constant expression of high levels of the undesired E6 and E7 mRNA molecules [49]. Consistent
with the multistep nature of tumorigenesis, cervical cancers may show additional cytogenetic
alterations as compared with adjacent high-grade dysplastic and/or carcinoma in situ lesions.
Low-grade dysplasia may be caused by infection with either low-risk (LR) or high-risk (HR)
HPV. Persistent (i.e., long-term) infection with a HR HPV type, which occurs in a minority of
infected women, is the most important risk factor for developing CIN III or pre-invasive cancer
(CIN III+). However, the magnitude of the risk depends not only on the given HPV type, but
even more on a HR variant within the given type (compare Table 6). In practical terms, HPV
persistence usually means that the same HPV genotype can be recovered from at least two or
more subsequently taken genital samples obtained over a period of 4–12 months. Persistent
infection may clear spontaneously, but less likely it does so in the course of longer duration.
Taken together, only some persistent infections progress to CIN III, and subsequently to
invasive cancer, but the HR HPV16 infections so such outcome much more likely than other
HPV types. The distinct biologic effects of HR E6 and E7 may present at least a partial
explanation of the differences in the likelihood of low-grade dysplasia progression, which
presence may not be consistently associated with the same probability of the progression to
high-grade lesion. Thus, most genital HPV infections are self-limited, and the majority would
clear within 12 months.
Taken together, the HPV genome persists within transformed host cells in two different forms:
as a non-integrated (episomal) circularized full-length vDNA and, less frequently, as a linear
and integrated vDNA sequence. There should be mentioned that during long-term latency,
the integration of HPV DNA may occur due to the linearization of the persisting circular vDNA
molecule. At integration, the HPV DNA chain gets either interrupted or partially deleted,
preferentially at nt 3362–3443 of the E2 ORF [50, 51], usually within the E2 gene ORF [52]. The
mixed (episomal as well as integrated) vDNA distribution pattern seems the most prevalent
physical state of HPV16 DNA found in ASCUS-graded smears (atypical cells of unknown
significance), but can also be detected in cervical scrapings which do not reveal dysplastic
changes. This indicates that HPV infection may not always cause dysplasia of the squamous
epithelium cells. The prevalence of the integrated HPV DNA sequence over the episomal
molecules then appears in a proportion of ASCUS-graded smears (sometimes characterized
by ASC-H cells) and in a proportion of LSIL smears, but later on becomes clearly prevalent in
the HSIL-grade smears and, of course, in cervical cancer. Women with the prevalence of
integrated HPV DNA were almost 10 years older than those with a predominating episomal
HPV DNA pattern, which points to a higher risk of HPV infection in women aged over 35
years [53].
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3. Overexpression of the p16/INK4A regulatory polypeptide in dysplastic
and/or proliferating cells
The aim of our further considerations was to assess the role of p16/INK4A (inhibitor kinase)
protein, which is, as a rule, overexpressed in cells revealing increased E7 polypeptide produc‐
tion. The p16/INK4A (inhibitor kinase) polypeptide is a cellular regulatory protein, which
inhibits the cyclin-dependent kinases (especially cdk4 and cdk6) associated with cyclins D and/
or E. These kinases, if activated, phosphorylate the retinoblastoma phosphoprotein (pRb)
complex, which in turn, releases the transcription factor E2F, which is bound in inactive form
in non-dividing cells. Under physiological conditions (in normal cells), the Rb protein liberated
from the disrupted complex has a feedback effect on p16 expression [47]. Since the E2 poly‐
peptide binds to LCR, the presence of E2 in cells carrying the episomal (i.e., non-integrated)
HPV DNA may efficiently control the transcription of mRNA encoding the E6/E7 oncoproteins
[54]. In contrast, in cells which carry the integrated HPV genome, the E2 polypeptide produc‐
tion stops, since the E2 ORF becomes disrupted. Therefore, the E2 but also the E1 proteins (both
Figure 1. Different patterns of positive p16 staining in CIN I/LSIL. Upper line: continuous staining of p16 antigen of
low (A) and/or high intensity (B) confined to the lower spinous layer and/or to the transit amplifying cells, which are
situated in parabasal location just adjacent to the p16 negative basal stem cells. No dysplasia can be seen. Line below:
staining of p16 antigen in a thin layer of dysplastic cells at parabasal area showing signs of HPV infection such as koi‐
locytes (in the left, C). Bottom in the right (D): progressed dysplasia of the basal layer in part involving the stem cells,
which cannot be clearly recognized.
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closely involved in the maintenance of long-term latency) may be missing in dysplastic
and/or HPV-transformed cells. Unlike to transformed cells, their production becomes down-
regulated in the late phase of vegetative (productive) virus replication cycle. It can be stated
that in HPV transformed cells, the expression of p16/INK4A protein increases proportionally
to elevated levels of the increasing expression of the virus-coded E7 polypeptide, since both
rise in the absence of E2 protein [55–58]. The p16/INK4 mRNA more stable and is present in
higher levels in the cells in which the HPV DNA sequence had been integrated [59]. The
quantification real-time–polymerase reaction (qRT PCR) is useful to identify the levels of
transcripts encoding the p16 polypeptide in cervical smears of patients obtained for diagnostic
purpose, an approach which is more tedious as the antigen staining, but is similarly sensitive
and occasionally may yield more confident results. The p16 mRNA was present in 30% of LGSL
but in 75% of HGSIL cases reaching a rate of 85.7% in squamous cell carcinoma cases [60].
The Bethesda scoring system, originally destined for vaginal/cervical smears [1988/1989], has
been later adopted for the cervical biopsies at histologic examination. This has happened
regardless to the fact that pathologists already had their own nomenclature, which is still in
use for cervical biopsy grading widely known as cervical intraepithelial neoplasia (CIN). The
dysplastic cells showing a diploid nuclear pattern are characterized by the loss of polarity,
crowding, overlapping disorganization, and anisocytosis [61]. Therefore, the stage of CIN I
dysplasia cannot be regarded for a truly neoplastic process. At cytological level, the dysplastic
cells show altered nuclear-to-cytoplasm (N/C) ratio as well as wrinkling and thickening of
nuclear membrane (Table 4) so that any CIN I grade changes may correspond to the entity of
LSIL [62]. In mild forms of CIN I/LSIL, the dysplastic cells occupy the parabasal layer only but
form a continuous zone within the lower third of cervical squamous epithelium, in the so-
called lower squamous layer along with the transit amplifying cells, which early dysplasia can
be better recognized by the p16 antigen staining (Figure 1). Summing up the results of p16
antigen staining in biopsy sections graded CIN I/LSIL, Yildiz et al. [63] could distinguish the
continuous parabasal staining of higher intensity (Figure 1B), from parabasal staining of lower
intensity (Figure 1A). In addition, they described the scattered form of positive p16 staining
of single and/or small groups of upper squamous epithelium cells, which do not correspond
to the suprabasal layer of lower squamous epithelium or the transit epithelium cells (Figure
2D). The production of p16 protein to an extent stainable with the commercially available anti-
p16 monoclonal antibody (for example the CINTec histology kit) has been attributed to the
stimulation of CDKN2A gene (encoding the p16 protein) by the stimuli activated via alterna‐
tive receptor pathways regulating the transient reactive cell proliferation. This situation should
be strongly distinguished from dysplasia, where the cell growth regulation undergoes some
kind of dysregulation (for example, by the viral oncogenic polypeptide E7) that causes the
switch to an autonomic growth due to repeated cell divisions. Thus, the increased p16
expression in single epithelium cells in a location where the E7 polypeptide may not be present
may be related to HPV infection. Noteworthy, older textbooks before the introduction of p16
staining [64] referred to the histological picture of chronic cervicitis characterized by with
hyperemia and round cell (lymphocyte) infiltration of the underlying connective tissue in
addition to the reactivity and dilution would also influence the p16 antigen staining results
ranging from clearly negative to false positive for above-mentioned reasons (Figure 3). During
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the last years, several big companies introduced automatic staining procedures, which on one
hand standardized the staining intensity as well as its color, but on other hand, new staining
variations appeared between different laboratories. Therefore, in cases suspicious for CIN I/
LSIL, or if thep16 staining reveals a faint reactivity or shows a distribution other than parabasal,
or does not correspond to a dysplastic cells area as seen in a parallel HE stained section, the
Figure 2. Metaplasia and/or focal dysplasia suspicious for CIN I /LSIL. Line above (A and B; C in the middle): transi‐
tion of squamous epithelium into a metaplastic area. The cells positive for p16 antigen correspond to the foci of meta‐
plasia (confluent staining), but single p16 positive squamous epithelium cells can be seen as well (A). The area of
metaplasia is rich of scattered Ki-67 positive nuclei, while the regularly lined positive nuclei belong to the basal stem
cells (C). The line below depicts a reactive proliferation of squamous epithelium (D and E) growing into the cervical
gland at the squamocolumnar junction. The positive p16 staining is not precisely parabasal, but corresponds to an ini‐
tial focus of dysplasia within the lower and/or medium squamous layers (shown by arrow at HE staining). The other‐
wise dispersed p16 antigen positive squamous cells may be unrelated to HPV infection.
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prognostic value of positive p16 staining should be interpreted along with the outcome of the
HPV DNA test.
Figure 3. Examples of either negative (A, upper line) and/or midzonal (lower line, B and C) p16 antigen staining. Both
examples show non-parabasal location of the p16 positive cells in the upper (rather than in the lower) squamous layer.
The staining is of nearly confluent (B) or focal (C) distribution and often corresponds to the localization of koilocytes.
Therefore, it is suggestive to accompany cases of productive (vegetative) HPV replication. Such pattern of p16 antigen
staining may be suspicious of low-grade lesion (CIN I/LSIL), but should be combined with the HPV DNA test in order
to obtain a precise diagnosis.
If dysplastic cells occupy at least one half (exceeding one third) of the original squamous
epithelium thickness (but not the whole epithelium layer), the appropriate designation is CIN
II. The p16 antigen staining is therefore useful to meet the diagnosis of CIN II/HSIL, since it
allows to estimate the precise thickness of dysplasia involving the squamous epithelium
(Figure 4). In contrast, at the stage of CIN III/HSIL, the dysplastic cells can fully replace the
original epithelium (Figure 5). At progressed stage, the intensive staining of p16 polypeptide
can be found within the nuclei of dysplastic cells as well as in their cytoplasm. The dysplastic
cells in question show enlarged nuclei of ovoid shape, which are not equal in size. Since the
presence of p16 antigen is a hallmark for distinguishing the immortalized and/or dysplastic
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cells, at first glance, the site of outgrowth and/or proliferation of squamous epithelium into
cervical glands can be detected. The decreased availability of functioning Rb protein due to
overexpression of E7 polypeptide, not only leads to increased p16 production, but also explains
the higher frequency of nuclei positive for Ki-67 protein, a marker of cell division [65]. For
more precise grading of the SIL lesions by the Ki-67 antigen staining, Kruse et al. [66] suggested
to count the number of positive nuclei per 100 μm epithelium thickness starting from the
parabasal zone (stratification index). The authors in question found a satisfactory correlation
of 83% with the dysplastic squamous epithelium cells as seen in HE stained sections, but they
also noticed that parallel sections may not fully correspond to the previously cut block level.
Furthermore, as seen at our example of the CIN III/HSIL pattern shown on Figure 5C and
5D, while the p16 antigen staining involves the whole dysplastic cell layer, in the Ki-67 stained
section the calculation of stratification index may be less convenient. Taken together, staining
of parallel sections for Ki-67 and p16 antigens confirmed the usefulness of both markers, even
though the p16 marker is more suitable for practical reasons. On the other hand, the frequent
zonal distribution of p16 reactivity fits well with the extent of dysplasia CIN I lesion encom‐
passing less than one third of stratified epithelium. In the CIN II-graded lesion, the dysplastic
cells encounter the half or nearly two thirds of squamous epithelium (Figure 4), while in the
CIN III lesion a diffuse distribution of dysplastic cells involves the whole thickness of the
original squamous epithelium layer. Therefore, at least in biopsies, the staining for p16 antigen
alone has recently emerged as a reliable diagnostic marker suitable for quick orientation and
relevant demonstration of the extent dysplasia as well as for the search of potentially invasive
growth of squamous cell carcinoma cells penetrating the basement membrane (Figure 6).
Figure 4. Examples of different CIN II lesions and of the corresponding p16 antigen staining. Upper line (A and B):
confluent staining of p16 antigen at transition from stage CIN I (in the left half of the Figure) into stage CIN II (in the
right half of same Figure 1A). Figure 1B: The p16 positive dysplastic cells involve the lower and the medium squamous
layers but still not the whole epithelium; numerous koilocytes can be seen in the in-close vicinity of the p16 antigen
positive dysplastic epithelium cells. Bottom line (C and D): Extensive dysplasia involves the lower and medium squa‐
mous cell layers, but is still absent at thin superficial layer of flat granular cells. The distribution of p16 antigen staining
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corresponds to transition from CIN II into CIN III (the area enlarged at D is pointed by arrow). As shown in detail (D),
a few koilocytes may be still found.
Figure 5. High degree of dysplasia (CIN III/HSIL) which occupies the entire epithelium layer and carcinoma in situ.
Line above: Transition of squamous epithelium into dysplasia as shown by HE (B) and by p16 antigen staining (A).
Middle line: The CIN III/HSIL as seen by p16 and Ki-67 antigen staining (C and D). While the p16 positive dysplastic
cells occupy the whole epithelium, the nuclei of dividing cells are either round shaped and of regular size (basal stem
cells closely at the basement membrane) or show an irregular ovoid shape of varying in size (dispersed at whole dys‐
plastic layer but not each cell is positive). Bottom line: Carcinoma in situ proliferates into the surrounding connective
tissue (cells p16 positive) and into a cervical gland replacing the cylindric epithelium but still keeping the basement
membrane intact (E). The entirely dysplastic epithelium is positive for the p16 antigen; it shows loss of squamous dif‐
ferentiation along with extensive proliferative growth, but with the basement membrane preserved (F, no invasion at
the arrow area).
Figure 6. Carcinoma in situ (A) versus the invasive growth of spinocellular carcinoma (B) as related to the expression
of p16 polypeptide. Dysplastic cells, forming the carcinoma in situ (A) as well as the non-differentiated malignant cells
of invasive spinocellular carcinoma (B), are strongly positive for p16 and showing cytoplasmic as well as nuclear stain‐
ing. After disrupting the basement membrane, groups of carcinoma cells grow not only within the surrounding con‐
nective tissue, but invade some capillaries and/or small venules as well as lymphatic vessels (C, arrow). At low power
view, the origin of invasion can be recognized (D, arrow).
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Nevertheless, any such comparisons may suffer from possible imprecision, since the repeat‐
edly stained a tendency to worse grading at the primary evaluation of HE results. Namely, 3%
of Ki-67 stained sections were graded CIN I rather than CIN II as described in HE stained
sections. Alternatively, 14% cases graded CIN III in the HE stained sections were interpreted
CIN II according to the Ki-67 staining. A similar tendency to worse grading from the evalua‐
tion, the HE stained sections only was found by us in p16 staining [14]. According to our
experience, the viewing of parallel sections stained for p16 as well as Ki-67 antigen markers is
of great help at confirming the extent of dysplasia seen in CIN II and/or CIN III HSIL-graded
sections. In addition, it contributes to the correct evaluation of CIN I/LSIL lesions among which
the reactive and other non-neoplastic staining patterns should be distinguished [67].
According to Dray et al. [68], the CIN II/HSIL- and/or CIN III/HSIL-graded lesions were found
in 40.8% of cervical biopsies, while 14.3% showed the mild CIN I/LSIL lesion; the rest of 45%
revealed a range of non-dysplastic (inflammatory or reactive) changes. In the latter group, the
focal and weaker midzonal or superficial p16/INK4A immunostaining, suggestive of episomal
HPV infection, was noted in 10% of biopsies. As shown in our statistics concerning biopsies
in the year 2015 examined at the Pathology Diagnostic Center in Martin (Pathology 2, bottom
line in Table 11), the definitely positive CIN I/LSIL lesions were seen in 36% of biopsies (90
out of 250). These lesions showed parabasal dysplasia within the lower third of squamous
epithelium as well as koilocytes among adjacent squamous cells rarely involving the upper
squamous layer (Figure 1). A proportion of suspicious CIN I/LSIL cases revealed focal
dysplasia which, as a rule, correlated with the non-continuous p16 antigen positivity of
squamous epithelium (Figure 2). The CIN II- and/or CIN III-grade HSIL lesion was detected
in 37% of biopsies (89/250). The former showed dysplasia along with positive p16 staining
involving about the half of squamous epithelium (Figure 4), while by the latter, the entire
squamous epithelium layer was strongly positive for the p16 antigen (Figure 5). In CIN II cases
involving more than one third of squamous epithelium, in the lower as well as in upper
squamous layers occasional koilocytes found (Figure 4B and 4D). In clearly CIN III-graded
cases, the p16 positive dysplastic cells not only have replaced the whole squamous epithelium
but also showed extensive proliferative growth either into the cervical glands or into the
underlying connective tissue still with the basement membrane preserved (Figure 5E and 5F).
Nevertheless, similar proliferative growth might be occasionally found in CIN II/LSIL-graded
cases (Figure 4A–4C), but very rarely, even in the CIN I/LSIL focal lesion. (Figure 2D and 2E).
In general, the increasing incidence of the combined p16/Ki-67 staining indicates more severe
lesions: It may be positive by 26.8% of normal histology (missing dysplasia) cases, by 46.5% in
CIN I histology, by 82.8% of CIN II, and/or by 92.8% of CIN III-graded histology [69]. In our
hands, squamous epithelium showing no dysplasia was found in 55 out of 250 cases (20%) in
biopsies of the Pathology Department 2, but only 10% of biopsies in the Pathology Department
1 (Table 11). The findings in the absence of dysplasia fall into at least 2 groups (Figure 3): (1)
p16 negative cases showing neither dysplasia nor p16 antigen presence, and (2) cases of
positive p16 immunostaining in the non-dysplastic areas of squamous epithelium, especially
in its midzonal location, which does clearly differ from the parabasal distribution of p16
antigen. The p16 positive staining in the absence of dysplasia should be always examined for
HPV DNA presence, and otherwise, the diagnosis can be regarded either for incomplete or at
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least imprecise from the point of view future prognosis. Although there is good evidence that
p16/INK4A immunostaining correlates with the severity of cytological/histological abnormal‐
ities, the reproducibility might be limited also because of the insufficiently standardized
interpretation of p16 staining results [70].
4. The diagnostic value of cervical smears in carcinoma prevention
As already mentioned in Introduction, due to examination of cervical smears in Slovakia
during the last decade, the absolute number of cervical carcinoma cases as well as the morbidity
rate has considerably decreased. Preventive cytological examination, which started in our
country from 2006, and became especially frequent in the last 5–6 years (compare Table 1) in
part explains this favorable development. As shown in Table 4, in just one out of 10 diagnostic
centers serving for the population of approximately 2 million Slovak women in the age from
15 to 60 years, over 37,000 PA smears were enrolled from about 34,000 women were examined.
Figure 7. ASCUS- and/or LSIL-graded smears handled by the conventional PA method and stained for p16 antigen (A,
B) in comparison with the appearance of atypical and/or abnormal squamous cells as seen after Liqui-PREP staining
(C, D, E, and F). The upper line in the left depicts a group of atypical squamous epithelium cells with enlarged nuclei
(A) in comparison with a group of abnormal cells-graded LSIL (B), both stained for p16 antigen. The middle line in the
right (D) shows inflammation and metaplasia with a group of abnormal epithelium cells scored LSIL (pointed by ar‐
row), while in the middle line left a group of atypical cells with enlarged nuclei can be seen (ASCUS) some of which
being suggestive for LSIL (C) . The smear in the right, bottom line shows atypical cells along with the presence of koi‐
locytes (F). In the bottom line left (E), one of the Ki-67 positive abnormal squamous cells shows faint p16 antigen stain‐
ing in the cytoplasm (simultaneously stained for p16 as well as Ki-67 antigens).
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A positive rate of 4.6% experienced in our particular screening is in accord with the data
previously reported from the US [16]. Despite of the success of mass screening based on the
relatively simple PAP technique, improved cytological tests such as liquid-based cytology
(Liqui-PREP) were introduced to achieve more precise reading. The new approach resulted in
a significant decrease of low-quality samples [71], when allowing to identify and distinguish
the atypical epithelium cells allowing to identify and better distinguish the atypical epithelium
cells at their better visualization, which may be of great advantage especially for the recogni‐
tion of LSIL cases (Figure 7).
Figure 8. Examples of HSIL-graded smears: Above, in the left (A): The conventional PAP staining is of relatively good
quality achieved using the CYNTec staining kit for p16 antigen detection (positive). The rest (B, C, and D) of smears
were handled by liquid-based cytology and shows either groups or single dysplastic cells-graded HSIL (B, C) and/or
HSIL+ (at D, a single dysplastic cell with an extremely large hyperchromatic nucleus is shown suggestive of carcinoma
in situ). The bottom line (E and F) shows groups of distorted (shrunken) dysplastic epitelium cells stained with the
anti/p16/anti-Ki-67 MoAb mix (nuclei dark purple, cytoplasm contains many p16 antigen brown granules).
As mentioned above, the Bethesda Committee classification [72] and the suggested definitions
were later on slightly improved reaching the state which has become widely accepted [73].
Comparisons among laboratories showed that the diagnosis of ASCUS (atypical squamous
cells of undetermined significance) may be often used just to avoid clear-cut decision making.
Therefore, the principle has been be that this diagnostic category should not exceed 5–6% of
the total number of smears investigated. As stressed by Geisinger et al. [74], the main criterion
for the clear definition of SIL is the increased size of nucleus (<3 fold for ASCUS, >3 fold in
LSIL), increased intensity of chromatin staining and its altered internal structure (finely
granular chromatin structure and slight hyperchromasia in ASCUS, coarse chromatin and
definitely visible hyperchromasia in LSIL reports claimed the relative value of p16 staining in
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ASCUS smears, which may be positive in cases designated as p16 reactive ASC. The proportion
of p16 negative smears was reported for the highest in ASCUS (40%) and the lowest in HSIL
(5%) specimens [75, 76]. According to Grapsa et al. [77], the p16 staining is weak in LSIL
(compare Figure 7A), but strong in HSIL cases (Figure 8A and 8B). Thus, the faint p16 staining
argues against the diagnosis of LSIL, while p16 overexpression along with high levels of p53
favors the process of malignant transformation of the atypical squamous epithelium cells.
According to Shin et al. [78], the p16 antigen was found in 66.7% of ASCUS and 70% of LSIL
cases, confirming that detection of p16/INK4A protein can be used as adjunct test especially
at liquid-based cytology. However, several authors noticed a high degree of false p16 reactivity
within otherwise negative smears, especially in those containing atrophic cells [79]. They also
stressed that in such smears, the number of single p16 reactive atypical cells per the total cell
number of cells may not be significant. Such situation is less likely to appear in biopsy sections,
where typical confluent distribution of p16 antigen positive cells at the parabasal epithelium
layer is of essential help for correct interpretation of the result. In our previous paper [14], we
focused our interest on unclear and/or ASCUS-graded smears, which were found HPV DNA
positive by a probability of 8–10%, but have been p16 antigen positive with a higher probability
ranging from 32 to 61%. The wide range of p16 antigen false positivity of atypical cells was
found associated with the staining procedure itself, since the CYN-Tec cytology staining kit
showed more clear-cut results, allowing to distinguish the proportion of really p16 antigen
positive, but HPV unrelated atypical cells on hand, from artificially stained ones on other hand.
It should be stressed that in the ASCUS-graded smears but also in a great proportion of LSIL
scored smears the most important criterion still remains the evaluation of nuclear changes,
such as the altered N/C ratio, which should be considered for each particular p16 reactive cell.
The diagnosis of ASC gains some prediction value, if based on the presence of a few HSIL-like
cells (the so-called ASC-H). The latter points at a fast progression to HSIL from the very
beginning (Figure 8). Nevertheless, the ASC-H category was challenged by other investigators
as being problematic, since the morphologic difference in the appearance of such single
metaplastic and/or neoplastic cell is not always clear and opens the way to false positive as
well as false negative diagnoses [80–82]. Nuclear hyperchromasia and irregular nuclear
membrane contours count as the most reliable diagnostic feature in the so-called pre-neoplastic
atypia. The presence of such cells in the smears possibly corresponds to the dysplastic cells in
histological sections [83], which, however, cannot be present in the smear in the case of CIN I/
LSIL (compare Figure 1), but may be already easily collected in the cases of CIN II/HSIL
(compare Figure 4). For better orientation in the most uncertain cases, a short course of local
estrogen cream therapy followed by repeated PA tests has been suggested for helpful [84].
According to our experience, the relatively high percentage of p16 reactive atypical cells
causing false positive LSIL grading appears in smears if handled by the conventional PA
method. Therefore, the LBC should be preferred at repeated examination of patients which
had been selected according to the classical Papanicolaou diagnostic system (when scored PA
IIIa/IIIb roughly corresponding ASCUS and/or LSIL, as well as PA IV corresponding to HSIL
and/or even PA V). The advantage of recently introduced improved diagnostic approach can
be demonstrated on the results from the Cytology Laboratory (CL) of the St. Elisabeth Cancer
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Institute (SECI) in Bratislava obtained within the years 2012–2013. The total number of
gynecological cytology samples enrolled during the given period was 17,272, which corre‐
sponds to approximately 46% of samples examined at the Cytology Laboratories of Alpha
medical presented in Table 4. While Table 4 shows the positive rate of the screening from
samples enrolled by practitioners, the Cancer Institute samples were submitted by specialists
to whom the positively screened patients were sent for further care and/or treatment. There‐
fore, the diagnostic approach met was more complex combining the LBC technic (for example
the Liqui-PREP kit) along with the detection of HPV DNA in nearly 53% of samples reflects
the advantage of the interpretation of results, which have been achieved by comparison of both
methods (Table 9). When considering the fact there was no logical need to request the HPV
DNA test in the majority of negative cases enrolled (out of these 28% were tested for HPV only)
then in becomes clear that the number of smears complete by DNA testing prevailed not only
in essentially inevitable cases, such as ASCUS and LSIL, but by average the HPV DNA was
tested by a proportion of 52.3% of all smears examined. When considering all the important
facts mentioned, then the complete (dual examination) approach has been applied in 68% of
ASCUS/LSIL cases (shown in bold type). It comes from Table 10 that the HPV positive rates
ranged from 27 to 33% in ASCUS and/or LSIL cases, respectively, indicating that the probability
of further progression in these mild lesions could be quite low. In contrast, by the HSIL-graded
smears the HPV DNA test was positive in 92% of cases. The same was true for the combination
of positive HPV test with the p16 antigen staining. This was seen by 32% of LSIL-graded cases,
in which the probability of progression was then relatively high, since as has been such
transition really may occur by up to 15% of LSIL cases (citácia), which means that each second
such double positive LSIL case might progress into HSIL. As our statistics concerns, this was
really the case, but by a lower probability equal to one out of three LSIL cases. Byun et al. [85]
conducted a comparative study including the p16 INK4a/Ki-67 double staining as well as the
L1 capsid protein immunostaining along with human papillomavirus (HPV) DNA detection
and typing in 56 ASC-H or LSIL-H cases diagnosed by LBC stained smears came to the
conclusion that their approach was sufficient to predict CIN II+ and/or CIN III+ later on
diagnoses at histological examinations of biopsies obtained from patients who underwent
conization. Further interesting considerations are coming from the comparison of the biopsies
subsequently resulting from the previous cytological diagnostic based their histological
grading made at different Pathology Departments. While in the Diagnostic Center at the
Pathology in Martin revealed that the probability of negative and/or non-neoplastic findings
(including false positive and/or reactive staining) was approximately 22%. In contrast, the
probability of the occurrence of the same result at the Pathology Department of the Oncology
Institute in Bratislava was slightly below 10% only (Table 11). This difference in the negative
scoring of CIN lesions in cervical biopsies reflects a better forecast based on a complex
diagnostic approach, involving the use of LBC technology at repeated examination of cervical
smears with contemporary HPV DNA tests along with the staining of smears for at least two
serological markers. We believe that the cytological diagnosis should reflect a better degree of
cooperation between clinicians and laboratory workers. As seen according to the presented
algorithm, the suggested minimum of 2 or 3 colposcopic sessions may be satisfactory for
precise diagnosis (Figure 9). In positive cases (i.e., those graded over PA III according to
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conventional Papanicolaou system), the repeated smear taken should be handled by the LBC-
based technic and stained for at least two markers (p16 and Ki-67 and tested HPV DNA
presence.
Cytology Completed Not completed Total examined
Non-suspicious 63 (28%) 225 288
ASCUS 139 (59%) 96 (41%) 235
ASC-H 5 (63%) 3 8
LSIL 304 (68%) 143 (32%) 447
HSIL 124 (53%) 108 (47%) 232
SCa 0 4 4
Total 635 (52.3%) 579 1214
Abbreviations: LBC—liquid-based cytology; HPV—human papilloma virus; ASCUS—atypical squamous cells of
undetermined significance; ASC-H—Atypical squamous cells-cannot exclude high-grade squamous intraepithelial
lesion; LGSIL—Low-grade squamous intraepithelial lesion; HGSIL—High-grade squamous intraepithelial lesion; SCa
—squamous cell carcinoma.
* The CL is a part of the Pathology Department of the St. Elisabeth Cancer Institute, which also is a teaching center of
Slovak Postgraduate University in Bratislava
** Negative.
*** HPV DNA not tested.
Table 9. LBC examinations of cervical smears during the period of 2012–2013 at the CL of the St. Elisabeth Cancer
Institute, Bratislava.
Cytological
diagnosis
Number Antigenic
markers
HPV DNA test
Per cent* p16
positive
Ki-67
positive
p16+/
Ki-67+
Positive
alone
p16+/HPV+
Negative* 63 9.9 0 0 0 3 0
ASCUS 139 21.9 87 (63%) 7 4 38 (27%) 21 (15%)
ASC-H 5 0.8 2 2 2 2 2
LSIL 304 47.9 268 (88%) 66 114 99 (33%) 97 (32%)
HSIL 124 19.5 120 (96%) 106 103 114 (92%) 112 (90%)
SCa 0 0 0 0 0 0 0
Total 635 100% 477 181 223 256 (40%) 232 (37%)
LBC—liquid-based cytology; HPV—human papilloma virus; ASCUS—atypical squamous cells of undetermined
significance; ASC-H—Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion; LSIL—
Low-grade squamous intraepithelial lesion; HGSIL—High-grade squamous intraepithelial lesion; SCa—squamous cell
carcinoma.
* Calculated from the total completed examinations.
** Scored as non-suspicious, see also in Table 9.
Table 10. The completed LBC-based cervical smears according to staining procedures and correlated with the HPV
DNA test result.
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Cytological diagnosis Diagnosis at biopsy Examination
Non-neoplastic** CIN I CIN II CIN III SCa Number total
ASCUS 20 12 2 4 0 38 Histology
ASC-H 3 0 2 0 0 5 Histology
LSIL 0 56 0 0 0 56 Histology
HSIL 0 4 60 76 0 140 Histology
SCa 0 0 0 0 4 4 Histology
Total (Pathology 1) 23 (9.4%) 72 (30%) 64 (26%) 80 (33%) 4 (1.6%) 243 (100%) Histology
Example shown at Figure 2**, Figure 3 Figure 1 Figure 4 Figure 5 Figure 6
Pathology 2 55 (22%) 90 (36%) 46 (18%) 52 (21%) 7 (3%) 250 (100%) Histology
3/11 (27%) 7/8 (88%) HPV DNA
LBC—liquid-based cytology; HPV—human papilloma virus; ASCUS—atypical squamous cells of undetermined
significance; ASC-H—Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion; LGSIL—
Low-grade squamous intraepithelial lesion; HGSIL—High-grade squamous intraepithelial lesion; SCa—squamous cell
carcinoma; CIN—cervical intraepithelial neoplasia and its grading.
* Concerns the biopsies examined at CL of St. Elisabeth Cancer Institute.
** Includes the reactive not-dysplastic lesions, such as false positive p16 staining as well as the p16 negative (normal)
squamous epithelium.
*** The data concern the Diagnostic Center of Pathology Ltd, Alpha medical, Martin.
# Important notice: even though the proportion of patients in which the HPV DNA was tested at The Pathology center
was relatively low (12 and 15%, respectively), the application of a complex approach Figure 9 proven the prevalence of
HPV DNA presence by CIN III/HSIL.
Table 11. Correlations between cytology and biopsy during the same time period of 2013–2014 in two different
Pathology Departments.
Diagnosis Sample number HPV (all types) HR HPV genotypes HR total
Negative Positive HPV16 HPV 18 Not frequent**
ASCUS/LSIL 520 329 191 59 18 114 191 (34%)
HSIL 45 19 26 2 0 24 26 (57%)
Not determined 932 608 302 93 21 120 (25%)
* Department of Clinical Microbiology, Alpha medical Ltd, Ružomberok, suitable to recognize the genotypes.
** HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
Table 12. Results of HPV DNA testing by means of the Cobas 4800 equipment*.
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Figure 9. A simple algorithm allowing to assess the precise diagnosis of dysplasia and to estimate its prognosis (all the
basic information shown should be at disposal for exact decision making).
5. HPV DNA detection in association with cytological and histological
examinations
In countries where cytological diagnostic is widely used for screening, the most useful option
is to use HPV DNA testing especially for getting more reliable information allowing to
lengthen safely the next smear examination interval [86]. In general, the DNA tests are based
either on DNA/DNA hybridization (using labeled complementary DNA probes), or on
amplification of vDNA by polymerase chain reaction (PCR) as well as on DNA/RNA hybrid‐
ization (using complementary RNA probes) followed by visualization of the labeled hybrid
signal. Early approaches utilized various modifications of the vDNA to DNA probe hybridi‐
zation tests, such as in situ hybridization and/or various blotting techniques [87]. To improve
the PCR method, multiple primers for L1 and/or E1 gene amplifications have been introduced,
aiming to identify the most frequent genotypes (i.e., HPV 6, 11, 16, and 18) in a single-tube
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reaction [88]. The principle of multiple genotype amplification was further modified using
general primers (GPs), which flank the strongly conserved regions located either on L1
and/or E1 ORFs, enabling detection of a wide spectrum of genotypes [89]. The GPs annealed
not only to the ORFs of genotypes, which they had been designed for, but also to some another
which sequence was not known at that time (later on these were identified as HPV 13, 30, 31,
45, and 51). The consensus or general primer GP5+/GP6+ based procedure became widely used,
since it enabled the differentiation between several HR and LR HPV genotypes in a single
assay [90, 91]. The GP-PCR technique became further improved in order to detect more
genotypes (at least 14 HR HPV along with the 6 frequent LR HPV genotypes). In addition, it
was modified in order to visualize the reaction product by enzyme linked immunosorbent
assay, that is ELISA [92]. The high-risk types being assessed this way were, as a rule, HPV 16,
18, 31, 33, 39, 45, 51, 52, 56, 58, 59, 66, and 68, and the low-risk ones were at least HPV 6, 11, 40,
42, 43, and 44. Further improvements of GPs allowed their annealing to the DNA of additional
genotypes, such as HPV 26, 30, 53, 70, 73, 82, and 83, in order to increase the number of routinely
detectable genotypes to 27 out of the 40 possible mucosal human papillomavirus types [93].
Additional consensus primers, having been introduced for L1 ORF amplification, were further
modified to avoid synthesis of irreproducible fragments [94]. The latter primer set
(PGMY07/11) increased the number of multiple HPV genotype infections detected by adding
the rare genotypes such as HPV 26, 35, 42, 45, 52, 54, 59, 66, and 73. Any routine HR versus LR
HPV testing may be influenced by the DNA extraction technic, namely depending whether a
recommended manual extraction procedure or an automated extraction protocol supplied by
the manufacturer of given equipment was used [95]. To avoid the methodic variations,
automated vDNA extraction was recommended for HPV genotyping by both, the classical
PCR (GP5/GP6 primers) as well as for the real-time PCR-based quantitative TaqMan assay.
Further modification of HPV detection in the direction of immunochemistry has resulted into
an assay omitting vDNA amplification, while introducing the labeled signal amplification
instead. In a latter assay, the denatured vDNA was hybridized under high stringency condi‐
tions to single-stranded RNA probes either for LR genotypes (at least 6, 11, 42, 43, and 44) and/
or for HR genotypes (at least 16, 18, 31, 33, 35, 45, 51, 52, and 56). The RNA/DNA hybrid
complex was then bound to microplates (or tubes) coated with an alkaline phosphatase
conjugated monoclonal antibody, able to capture the specific RNA/DNA hybrid [96]. The
reaction is then visualized by addition of the chemilumiscent substrate, in which emission light
is amplified and measured in a luminometer; the results are expressed in relative light units
(RLU). This method is referred to as hybrid capture (HC). At its beginning HC showed lower
sensitivity, as compared to as few as 10–100 vDNA copies (about 100 fg HPV DNA) were
detectable per 1 ml sample when using the classical PCR. The recent HC2-based high-risk HPV
DNA test (Qiagen), which was previously used in the Alpha medical laboratory as well, detects
13 HR genotypes (HPV 16, 18, 31, 33, 35, 35, 39, 45, 51, 52, 56, 58, and 68) at a sensitivity of 1–
2 pg/ml (i.e., about 100,000 HPV DNA copies/ml). Another variation of this assay can be also
used for detection of at least 5 LR genotypes (HPV 6, 11, 42, 43, and 44). Recio et al. [97] used
the first generation HC test for investigating the HPV DNA presence in patients with ASCUS,
LSIL, HSIL, and carcinoma in situ smears, the latter being used as a relevant standard.
Altogether 44% of patients were tested positive, mainly for HR HPV genotypes. The authors
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concluded that testing of HPV DNA by the HC method is helpful for clinical diagnostic.
Monsenogo et al. [90] reported that the HC2 test as compared in 470 patients with the PCR-
based Roche Amplicor HPV test, reached an agreement of 96.2%; only 18 cases were found
discordant. It should be mentioned that the Amplicor HPV test identifies the PCR-amplified
vDNA by means of 13 HR-HPV genotype probes and that the vDNA is being obtained from
cervical cells collected into a transport medium [98]. In patients revealing ASCUS smears, both
tests for HPV DNA showed a positive rate of 42.3%, while in patients showing LSIL smears,
the HPV DNA positive rate was 66.3 and/or 66.8%, respectively, depending on the test
performed (the PCR-based test seemed in this case even less sensitive). In patients with HSIL
smears, the DNA was positive in both tests at the highest rate of 92.8%.
The HC2 high risk HPV DNA Test takes advantage of the Hybrid Capture 2 (HC2) technology;
it is a nucleic acid hybridization assay with signal amplification that utilizes microplate
chemiluminescent detection for the qualitative detection of 13 high-risk HPV types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 68) in cervical specimens. Specimens containing the target DNA
hybridize with a specific HPV RNA probe. The resultant RNA:DNA hybrids are captured onto
the surface of a microplate well coated with antibodies specific for RNA:DNA hybrids.
Immobilized hybrids are then reacted with alkaline phosphatase conjugated antibodies
specific for the RNA:DNA hybrids and detected with chemiluminescent substrate. Several
alkaline phosphatase molecules are conjugated to each antibody. Multiple conjugated
antibodies bind to each captured hybrid resulting in substantial signal amplification. In
contrast to the HC technology, the Cobas® 4800 Human Papillomavirus (HPV) Test is a
qualitative in vitro test for the detection of human papillomavirus in cervical specimens. The
test utilizes amplification of target DNA by the polymerase chain reaction (PCR) and nucleic
acid hybridization for the detection of 14 high-risk HPV types in a single analysis. The test
specifically identifies HPV16 and HPV18 while concurrently detecting the other high-risk
types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) at clinically relevant infection levels. The
Cobas® 4800 HPV Test primers define a sequence of approximately 200 nucleotides within the
polymorphic L1 region of the HPV genome. An additional primer pair would target the human
β-globin gene (330 bp amplicon) to provide a process control. A pool of HPV primers present
in the Master Mix is designed to amplify HPV DNA from 14 high-risk types (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, and 68). The detection of amplified DNA is performed during
thermal cycling using oligonucleotide probes labeled with four different fluorescent dyes. The
amplified signal from twelve high-risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and
68), is detected using the same fluorescent dye, while HPV16, HPV18, and β-globin signals are
each detected with their own dedicated fluorescent dye. Fluorescent oligonucleotide probes
bind to polymorphic regions HPV and human β-globin gene within the sequence defined by
primers.
Summing up, the DNAs can be distinguished according to (1) the ability to identify a pool of
high-risk HPV types, with or without genotypization of the most common high-risk viruses
(i.e., HPV16 and 18) or (2) to detect a broad spectrum of oncogenic and non-oncogenic HPVs
along with individual genotyping. While the assays of the first group are mainly used in
screening programs, where there is no clinical benefit from the knowledge of specific HPV
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types, the assays of the second group are primarily used in HPV surveillance studies and to
monitor the eventual spreading of particular viral types in vaccinated women [99]. The HPV16
and HPV18 genotyping, for its high specificity, have been included in the US guidelines for
the triage of HPV positive and cytology negative women [100]. In general, the probability of
developing precancerous (HSIL) lesions was high in women who were LSIL as well as DNA
positive; a lower, but still medium probability for developing cancer was found in HPV DNA
positive, but by cytology negative women. The lowest probability was noted in HPV negative
but ASCUS/LSIL positive cases. Similar findings were observed in the Microbiology Depart‐
ment of Alpha medical (Table 12) showing that the positive rate of HR genotypes was the
highest in HSIL cases, the closet in cases with not precisely determined diagnosis. As stressed
by Mandelblatt et al. [101], screening of HPV plus patients with LSIL tests within 2 years
appears to save lives and is more reasonable than performing the cytology test alone. Another
large cohort study in US (performed from 2003 to 2005) found that women aged less than 30
who have ASCUS-grade smears showed HPV positive rate at 53% [102]. On the other hand,
women older than 30 years with NIL PAP test were HPV (HC2) positive at a rate of 9%. Since
ASCUS smear diagnosis is a clinical and prognostic challenge, it should be combined with
HPV testing and repeatedly investigated to show whether or not the transition to HSIL occurs
[103]. Also in this follow up, a relatively low proportion (6.7%) of ASCUS positive patients
developed HSIL or cancer. Among the patients with HSIL smears, up to 98% was found HPV
565 DNA positive; theoretically such women harbor the integrated incomplete genome in the
cervical tissue. It was concluded that the residual specimens collected from routine cervical
cytology in ASCUS cases could provide additional information about the HPV DNA status
that is of substantial help by identifying those patients, who are likely to develop HSIL,
especially if they test positive for the HPV DNA presence.
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